Change Healthcare develops module to reduce denials of claims

Change Healthcare has announced the development of a module for their Assurance Reimbursement Management program that assists providers submit claims. 

The Assurance Attach Assist predicts what documentation a payer may require preventing the denial of a claim due to missing documents. With the module, providers can reduce the main cause of claims denials. The module allows users to electronically submit attachments during and after claim submission, which are then tracked to maintain visibility until the claim is accepted.

Attach Assist supports Medicare, Medi-Cal, Blue Cross California Medi-Cal, Anthem Blue Cross–California, Anthem Blue Cross Blue Shield–Nevada, Anthem Blue Cross Blue Shield–Colorado, PacificSource Health Plans and Washington Medicaid. By providing automation to the claims process, the module decreases documentation-related denials and improves efficiency of claims to grow revenue.

"The key to reducing denials is to address requirements on the front end before they become problems on the back end," said Marcy Tatsch, senior vice president and general manager of Reimbursement and Analytics Solutions at Change Healthcare. "There are so many factors that can trigger a denial. Providers need proactive technology that helps them anticipate and eliminate issues before they cause a denial. We continue to invest in the tools that help our customers reduce the administrative burden and speed revenue cycle velocity."

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.